While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear ...
Hosted on MSN
Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.
Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets ...
The future of cancer drug research just might be in Omaha, Nebraska, between a Panda Express and a Mattress Firm. A big draw is speed: Nordquist says he can open a trial in as little as two weeks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback